The results of the WHO's solidarity trial found that remdesivir, hydroxychloroquine, lopinavir/ritonavir and interferon had little or no effect on 28-day mortality.
India will reassess the protocol for COVID-19 treatment in the wake of interim results published by the World Health Organization of the trial which found that remdesivir, the antiviral drug widely prescribed against coronavirus, has no substantial effect on mortality, initiation of ventilation or duration of hospital stay.
Hydroxychloroquine (HCQ), the anti-HIV combination of lopinavir and ritonavir, and the immunomodulator interferon were also found to have little to no effect on COVID-19 patients.
The protocol for the treatment of coronavirus patients will be reviewed in the next joint task force meeting headed by Dr VK Paul, member (health), Niti Aayog, and director-general, Indian Council of Medical Research (ICMR), Dr Balram Bhargava.
Frequently Asked Questions
A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.
There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.
Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
"Yes, we will be revisiting the clinical management protocol in the light of new evidence before us," Bhargava told Hindustan Times.
The results of the solidarity trial conducted on 11,266 hospitalised patients in 30 countries found that remdesivir and three other repurposed drugs -- hydroxychloroquine, lopinavir/ritonavir and interferon -- had little or no effect on 28-day mortality.
WHO discontinued hydroxychloroquine and lopinavir-ritonavir arms in July following the interim results.
WHO said the results of the trial are under review for publication in a medical journal and have been uploaded as a preprint at medRxiv - a non-peer-reviewed journal.
The findings hold significance as the use of remdesivir (for restricted emergency use purposes) has been recommended for treating coronavirus patients in the moderate stage of the illness as investigational therapies" in Clinical Management Protocol for COVID-19 issued by the Union health ministry.
Other uses of the drugs, for example, in treatment of patients in the community or for prevention, would have to be examined using different trials, the WHO said.
The Indian Council of Medical Research (ICMR) was also an active partner in the Solidarity Therapeutics Trial conducted under the aegis of the WHO.
"The trial tested four repurposed drugs, namely, remdesivir, interferon 1a, lopinavir/ritonavir and hydroxychloroquine. The interim analysis showed no benefits of remdesivir in any groups of COVID-19 (asymptomatic/mild/moderate/severe/critical) patients," ICMR said in a statement on October 16.
"The trial comprised 26 actively randomising sites with 937 participants in India. We are grateful to the trial participants and their families for contributing to these crucial findings," Samiran Panda, Head, ICMR-Division of Epidemiology and Communicable Diseases (ECD), and Director, ICMR-NARI said.Click here for Moneycontrol's full coverage of the COVID-19 vaccine